View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
February 28, 2022

Ranked: industry sponsors with the most clinical trials in 2021

There were more industry-sponsored clinical trials in 2021 than 2020, as well as fewer suspended, terminated or withdrawn trials.

By GlobalData Healthcare

The backlog of trial disruptions due to the impact of the Covid-19 pandemic in 2020 has led to an increase in industry-sponsored trials for 2021. Compared with 2020, the number of ongoing and planned trials increased significantly and the number of suspended, terminated or withdrawn trials decreased. This could be attributed to the normal resumption of trials after delays from the Covid-19 pandemic. Out of the 9,854 trials with a 2021 start date, 6,185 trials were ongoing and recruiting participants, 3,925 trials were in planned status, 1,049 trials were completed, and 319 trials were suspended, terminated or withdrawn.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Within industry-sponsored trials, Novartis tops the clinical trial count with 135 trials, followed by AstraZeneca with 125 trials and Johnson & Johnson with 117 trials. AstraZeneca was also in the top three industry sponsors by trial count in 2020. Upon further breakdown, Novartis had the most ongoing, recruiting trials with 103 trials, followed by AstraZeneca with 85 trials and Johnson & Johnson with 80 trials.

When analysing these sponsors further, Novartis trials mainly focused on oncology therapeutics, with chronic myelocytic leukaemia and non-small cell lung cancer being the lead indications. This correlates to reports of Novartis further developing its oncology pipeline at the beginning of 2021 in collaboration with BeiGene to help develop, manufacture and market BeiGene’s Tislelizumab, an anti-PD-1 monoclonal antibody, in North America, Europe and Japan.

AstraZeneca’s top pipeline indications both focused on oncology and respiratory therapeutics, with non-small cell lung cancer, solid tumour, Covid-19 and asthma being the top indications. Meanwhile, Johnson & Johnson’s top indications focused mainly on viral infections, specifically hepatitis B, respiratory syncytial virus (RSV) and Covid-19.

Both companies were under the spotlight last year due to blood clot issues related to their respective adenovirus-vectored Covid-19 vaccines. This highly publicised issue led to certain nations halting or delaying the use of their Covid-19 vaccines, while a segment of the public either delayed their vaccinations or opted for another Covid-19 vaccine if one was available.

Also in 2021, AstraZeneca released plans to produce the next generation of inhalers, which will have 'near-zero Global Warming Potential propellant', meaning lower greenhouse gas emissions. This correlates to asthma being the company’s key indication.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena